EVE Health Group Limited (ASX:EVE)

Market Cap	8.81M +67.0%
Revenue (ttm)	1.36M -34.2%
Net Income	-1.62M
EPS	-0.01
Shares Out	352.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	340,074
Open	0.0260
Previous Close	0.0260
Day's Range	0.0250 - 0.0260
52-Week Range	0.0170 - 0.0380
Beta	0.53
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 4, 2026

About EVE Health Group

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2003
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EVE

Financial Performance

In fiscal year 2025, EVE Health Group's revenue was 1.73 million, a decrease of -18.70% compared to the previous year's 2.13 million. Losses were -1.58 million, -16.89% less than in 2024.